On Sept. 7, 2023, Merck announced that the European Commission (EC) had approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus.

The ECﾒs decision follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) received on July 20, 2023. The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.